Skip to main content
https://pbs.twimg.com/media/GtZSIuzWsAAk4_n.jpg
APEX study Ph3 RCT Guselkumab In BioNaive active PsA w/ erosions>=2 wk 24 ACR20 GUS Q4W 67% Q8W 68% vs PBO 47% Less Rx progression in both Q4W & Q8W vs. PBO #EULAR2025 @RheumNow LB0010 https://t.co/OVDWWECtOZ
Aurelie Najm
14-06-2025
×